200 related articles for article (PubMed ID: 32582872)
21. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control.
Emu B; Sinclair E; Hatano H; Ferre A; Shacklett B; Martin JN; McCune JM; Deeks SG
J Virol; 2008 Jun; 82(11):5398-407. PubMed ID: 18353945
[TBL] [Abstract][Full Text] [Related]
22. IFNα induces CCR5 in CD4
Le Buanec H; Schiavon V; Merandet M; How-Kit A; Song H; Bergerat D; Fombellida-Lopez C; Bensussan A; Bouaziz JD; Burny A; Darcis G; Sajadi MM; Kottilil S; Zagury D; Gallo RC
Commun Med (Lond); 2024 Mar; 4(1):52. PubMed ID: 38504093
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic Controllers.
Gonzalo-Gil E; Ikediobi U; Sutton RE
Yale J Biol Med; 2017 Jun; 90(2):245-259. PubMed ID: 28656011
[TBL] [Abstract][Full Text] [Related]
24. HIV controllers with different viral load cutoff levels have distinct virologic and immunologic profiles.
Côrtes FH; Passaes CP; Bello G; Teixeira SL; Vorsatz C; Babic D; Sharkey M; Grinsztejn B; Veloso V; Stevenson M; Morgado MG
J Acquir Immune Defic Syndr; 2015 Apr; 68(4):377-385. PubMed ID: 25564106
[TBL] [Abstract][Full Text] [Related]
25. Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers.
Li JZ; Segal FP; Bosch RJ; Lalama CM; Roberts-Toler C; Delagreverie H; Getz R; Garcia-Broncano P; Kinslow J; Tressler R; Van Dam CN; Keefer M; Carrington M; Lichterfeld M; Kuritzkes D; Yu XG; Landay A; Sax PE;
Clin Infect Dis; 2020 Apr; 70(8):1636-1642. PubMed ID: 31131858
[TBL] [Abstract][Full Text] [Related]
26. Elite controllers long-term non progressors present improved survival and slower disease progression.
Capa L; Ayala-Suárez R; De La Torre Tarazona HE; González-García J; Del Romero J; Alcamí J; Díez-Fuertes F
Sci Rep; 2022 Sep; 12(1):16356. PubMed ID: 36175445
[TBL] [Abstract][Full Text] [Related]
27. Effect of antiretroviral therapy on HIV reservoirs in elite controllers.
Chun TW; Shawn Justement J; Murray D; Kim CJ; Blazkova J; Hallahan CW; Benko E; Costiniuk CT; Kandel G; Ostrowski M; Kaul R; Moir S; Casazza JP; Koup RA; Kovacs C; Fauci AS
J Infect Dis; 2013 Nov; 208(9):1443-7. PubMed ID: 23847057
[TBL] [Abstract][Full Text] [Related]
28. Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy.
Jilg N; Garcia-Broncano P; Peluso M; Segal FP; Bosch RJ; Roberts-Toler C; Chen SMY; Van Dam CN; Keefer MC; Kuritzkes DR; Landay AL; Deeks S; Yu XG; Sax PE; Li JZ;
J Infect Dis; 2020 Nov; 222(11):1837-1842. PubMed ID: 32496516
[TBL] [Abstract][Full Text] [Related]
29. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers.
Hunt PW; Landay AL; Sinclair E; Martinson JA; Hatano H; Emu B; Norris PJ; Busch MP; Martin JN; Brooks C; McCune JM; Deeks SG
PLoS One; 2011 Jan; 6(1):e15924. PubMed ID: 21305005
[TBL] [Abstract][Full Text] [Related]
30. Nef Proteins from HIV-1 Elite Controllers Are Inefficient at Preventing Antibody-Dependent Cellular Cytotoxicity.
Alsahafi N; Ding S; Richard J; Markle T; Brassard N; Walker B; Lewis GK; Kaufmann DE; Brockman MA; Finzi A
J Virol; 2015 Dec; 90(6):2993-3002. PubMed ID: 26719277
[TBL] [Abstract][Full Text] [Related]
31. HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses.
Owen RE; Heitman JW; Hirschkorn DF; Lanteri MC; Biswas HH; Martin JN; Krone MR; Deeks SG; Norris PJ;
AIDS; 2010 May; 24(8):1095-105. PubMed ID: 20400885
[TBL] [Abstract][Full Text] [Related]
32. Impaired Downregulation of NKG2D Ligands by Nef Proteins from Elite Controllers Sensitizes HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.
Alsahafi N; Richard J; Prévost J; Coutu M; Brassard N; Parsons MS; Kaufmann DE; Brockman M; Finzi A
J Virol; 2017 Aug; 91(16):. PubMed ID: 28615199
[TBL] [Abstract][Full Text] [Related]
33. Maintenance of HIV-Specific Memory B-Cell Responses in Elite Controllers Despite Low Viral Burdens.
Buckner CM; Kardava L; Zhang X; Gittens K; Justement JS; Kovacs C; McDermott AB; Li Y; Sajadi MM; Chun TW; Fauci AS; Moir S
J Infect Dis; 2016 Aug; 214(3):390-8. PubMed ID: 27122593
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes and antiretroviral therapy in 'elite' controllers: a review of the literature.
Crowell TA; Hatano H
J Virus Erad; 2015 Apr; 1(2):72-77. PubMed ID: 27123315
[TBL] [Abstract][Full Text] [Related]
35. Differential microRNA expression profile between stimulated PBMCs from HIV-1 infected elite controllers and viremic progressors.
Egaña-Gorroño L; Escribà T; Boulanger N; Guardo AC; León A; Bargalló ME; Garcia F; Gatell JM; Plana M; Arnedo M;
PLoS One; 2014; 9(9):e106360. PubMed ID: 25225963
[TBL] [Abstract][Full Text] [Related]
36. Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control.
Pohlmeyer CW; Gonzalez VD; Irrinki A; Ramirez RN; Li L; Mulato A; Murry JP; Arvey A; Hoh R; Deeks SG; Kukolj G; Cihlar T; Pflanz S; Nolan GP; Min-Oo G
J Virol; 2019 Apr; 93(7):. PubMed ID: 30700608
[TBL] [Abstract][Full Text] [Related]
37. Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers.
Ganesh A; Lemongello D; Lee E; Peterson J; McLaughlin BE; Ferre AL; Gillespie GM; Fuchs D; Deeks SG; Hunt PW; Price RW; Spudich SS; Shacklett BL
AIDS Res Hum Retroviruses; 2016 Aug; 32(8):791-800. PubMed ID: 27019338
[TBL] [Abstract][Full Text] [Related]
38. An open label randomized controlled trial of atorvastatin versus aspirin in elite controllers and antiretroviral-treated people with HIV.
Mystakelis HA; Wilson E; Laidlaw E; Poole A; Krishnan S; Rupert A; Welker JL; Gorelick RJ; Lisco A; Manion M; Baker JV; Migueles SA; Sereti I
AIDS; 2023 Oct; 37(12):1827-1835. PubMed ID: 37450602
[TBL] [Abstract][Full Text] [Related]
39. Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection.
Crowell TA; Gebo KA; Blankson JN; Korthuis PT; Yehia BR; Rutstein RM; Moore RD; Sharp V; Nijhawan AE; Mathews WC; Hanau LH; Corales RB; Beil R; Somboonwit C; Edelstein H; Allen SL; Berry SA;
J Infect Dis; 2015 Jun; 211(11):1692-702. PubMed ID: 25512624
[TBL] [Abstract][Full Text] [Related]
40. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters.
Pereyra F; Palmer S; Miura T; Block BL; Wiegand A; Rothchild AC; Baker B; Rosenberg R; Cutrell E; Seaman MS; Coffin JM; Walker BD
J Infect Dis; 2009 Sep; 200(6):984-90. PubMed ID: 19656066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
